Evidence map›Paper›PMID 42834034›Full record

Trial reportTranslational psychiatry2026

Subacute effects of ketamine on neural correlates of reward processing.

Elisa Briem, Peter Stöhrmann, Gregor Dörl, Christian Milz, Gabriel Schlosser, Manfred Klöbl, Murray Reed, Matthieu Atger, Clemens Schmidt, Samantha Graf and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elisa BriemDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0009-0007-4311-4031
Peter StöhrmannDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-7324-0414
Gregor DörlDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Christian MilzDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-1347-0744
Gabriel SchlosserDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Manfred KlöblDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Murray ReedDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Matthieu AtgerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0009-0001-1054-8374
Clemens SchmidtDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-3138-6869
Samantha GrafDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Maximilian KathoferVienna Cognitive Science Hub, University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-8249-3237
Godber Mathis GodbersenDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-9739-0724
Julia Sophia CroneVienna Cognitive Science Hub, University of Vienna, Vienna, Austria.
Rupert LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. rupert.lanzenberger@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-4641-9539
Marie SpiesDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Funding

Medizinische Universität Wien (Medical University of Vienna) SO68900012Universität Wien (University of Vienna) SO68900012
6 · The paper itself

Abstract

Ketamine induces a sequence of temporally distinct effects on brain function, yet its impact on reward processing beyond the acute post-administration phase remains unclear. In this single-blind, placebo-controlled, crossover study, 28 healthy participants received 0.5 mg/kg racemic ketamine or placebo via a 40 min intravenous infusion. Functional magnetic resonance imaging was acquired approximately 5 h post-infusion during the Monetary Incentive Delay (MID) task, targeting the subacute phase after resolution of acute dissociative effects. Plasma concentrations of ketamine and norketamine were obtained for pharmacokinetic modeling and area under the curve estimation. At 5 h post-administration, ketamine did not significantly modulate brain activation during the MID task in either ROI-based or whole-brain analyses, despite measurable subjective drug effects. Pharmacokinetic modeling yielded ketamine and norketamine concentration-time profiles consistent with expected pharmacokinetic patterns, however, neither individual drug exposure nor psychometric measures showed robust associations with MID task-related neural activation. These findings suggest an absence of detectable task-evoked effects under the present methodological conditions. When considered alongside prior work, they are consistent with the possibility that ketamine's effects on reward circuitry are time-sensitive and may be more prominent during the acute post-administration phase or in clinical populations with pre-existing reward dysfunction.

Indexed as

BrainExcitatory Amino Acid AntagonistsKetamineRewardAdultCross-Over StudiesFemaleHumansMagnetic Resonance ImagingMaleSingle-Blind MethodYoung AdultExcitatory Amino Acid AntagonistsKetaminenorketamine

Identifiers

PMID42834034
PMCPMC13639076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.